Leptomeningeal Cancer Cell Diagnostic Assay Gets Clinical Trial Implementation
The tumor cell enumeration assay is a diagnostic test that is promising for establishing the diagnosis of leptomeningeal metastases.
The tumor cell enumeration assay is a diagnostic test that is promising for establishing the diagnosis of leptomeningeal metastases.
The DecisionDx-SCC test guides adjuvant radiation therapy (ART) decisions for patients with squamous cell carcinoma (SCC).
This collaboration aims to deliver AI diagnostic tools that aid urologists in the detection, surgery, and post-treatment surveillance.
The study’s impact is multifaceted, potentially influencing the development of non-invasive diagnostic tests and novel medicines.
Read MoreA new molecular test identifies the presence of brain tumors by measuring abnormal genetic material shed by tumors and circulating in CSF.
Read MoreLucid Diagnostics Inc. has contracted with the Ancira Auto Group to offer EsoGuard esophageal precancer testing to eligible employees.
Read MoreIn the U.S. and other Western countries, a form of esophageal and stomach cancer has risen dramatically over the last five decades.
Read MoreBlood disorders known as MDS are difficult to diagnose putting patients at increased risk for treatment mistakes from misdiagnosis.
Read MoreBy testing a range of therapies in organoids grown from the patient’s own tumor sample, SEngine’s PARIS Test identified off-label therapy that proved highly successful for one ovarian cancer patient.
Read MorePrecipio Inc. and an academic healthcare institution will jointly develop a panel for Glioblastoma based on Precipio’s HemeScreen technology.
Read MorePrecipio’s HemeScreen Cytopenia panel enabled a patient’s diagnosis without the need for a painful, invasive bone marrow biopsy.
Read MoreResearchers found that a cancer stem cell test called ChemoID can accurately decide more effective treatments and lead to increased survival for patients with glioblastoma.
Read MoreResults from the Nordic Registry study demonstrated the benefits of blue light cystoscopy in detecting bladder cancer at the American Urological Association Annual Congress 2023.
Read MoreA simple blood draw can help determine if peptide receptor radionuclide therapy is effective in a patient with neuroendocrine cancer.
Read MoreScientists developed a test that was shown to be over 92% accurate at identifying patients with oral squamous cell carcinoma (OSCC).
Read MoreIVDR-certification has been granted for eight CytoCell FISH probes for patient management in haematological cancers and prenatal conditions.
Read MoreNew technology detects bladder cancer in both the clinic and operating room settings by using blue and white light, and an imaging dye.
Read MoreRapid Novor obtained the CLIA certification for its EasyM assay for Multiple Myeloma as a laboratory developed test.
Read More